Tweets by SSO 2024 Annual Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Recorded for On-Demand Viewing

Back

PSM

PSM Poster Presentations 2

P52: Updated Report of a Randomized Trial for Appendiceal Neoplasm Ten Years After Cytoreduction and HIPEC With Mitomycin vs. Oxaliplatin

Saturday, March 23, 2024

9:07am – 9:13am ET

Location: C110

Oral Poster Presenter(s)

Heidy Cos, MD

Fellow
Wake Forest Baptist Medical Center, United States

Submitter(s)

Heidy Cos, MD

Fellow
Wake Forest Baptist Medical Center, United States

Author(s)

Heidy Cos, MD

Fellow
Wake Forest Baptist Medical Center, United States
Edward A. Levine, MD

Chair Surgical Oncology
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Konstantinos I. Votanopoulos, MD, PhD, FACS

Professor Surgical Oncology
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
PS

Perry Shen, MD

Professor Surgical Oncology
Wake Forest Baptist Medical Center, United States
GR

Gregory Russell, BS, MS

Senior Biostatistician
Wake Forest Baptist Medical Center, United States
PM

Paul F. Mansfield, MD

Professor
MD Anderson Cancer Center, United States
KF

Keith F. Fournier, MD

Associate Professor
Division of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, United States, United States
David L. Bartlett, MD

Faculty
AHN
Pittsburgh, Pennsylvania, United States
GL

Grey Leonard, MD

Fellow
Wake Forest Baptist Medical Center, United States

Disclosure(s):

Konstantinos I. Votanopoulos, MD, PhD, FACS: Applied Organoids INC: Ownership Interest (Ongoing); Iovance Biotherapeutics: Stocks (Ongoing); Wake Forest University: Patent Beneficiary (Ongoing)

Introduction: Appendiceal cancer is a rare disease that has proven difficult to study in prospective trials. Our initial report showed minor hematologic toxicity with both Mitomycin and Oxaliplatin and similar 3-year overall and disease-free survival. We now report an update with 10 year follow up.

Methods: Patients with mucinous appendiceal neoplasms and evidence of peritoneal dissemination were enrolled in the Multicenter Randomized Trial to evaluating HIPEC with Oxaliplatin or Mitomycin. Overall survival and disease free survival were calculated at 10 years and compared between the groups.

Results:

121 patients were included in the study. The patients were 57% female, with a mean age of 55.3 years (range 22 to 82 years). The disease was low grade in 77% and high grade in 23%. The average peritoneal carcinomatosis index (PCI) score was 18 (SD=10) in the Mitomycin group and 17.9 (SD=9.4) in the Oxaliplatin group; p=0.94. The resection status in the Mitomycin group was R0=21%, R1=33%, R2a=39% and R2b=7%; in the Oxaliplatin group R0=23.3%, R1=38.3%, R2a=25%, R2b=10% and R2c=3.3%; p=0.35. The 10-year survival rate was 56.2% (SE 7.2) with Mitomycin and 47.5% (SE 8.4) with Oxaliplatin; p=0.83. The 10-year progression free survival rate in the Mitomycin group was 45.2% (SE 8.4) compared to 50.4% (SE 6.7) in the Oxaliplatin group, p=0.95. Median survival was 9.1 years after HIPEC with oxaliplatin, and median not reached for the Mitomycin group ( >5.6 years).

Conclusions: Oxaliplatin and Mitomycin have similar long-term efficacy for HIPEC in patients with appendiceal neoplasms and peritoneal dissemination. Long term survival is experienced by most patients after CRS and HIPEC for appendiceal neoplasms.

Learning Objectives:

Describe outcomes of Cytoreduction and HIPEC for appendiceal neoplasms
Compare outcomes of HIPEC with Oxaliplatin versus Mitomycin C in patients with appendiceal neoplasms
List long term survival rates for appendiceal neoplasm after treatment with HIPEC and cytoreduction